Curated News
By: NewsRamp Editorial Staff
August 07, 2025
Annovis Bio Secures Patent for Breakthrough Neurodegenerative Treatment
TLDR
- Annovis Bio secures a competitive edge with its extended patent protection for buntanetap until 2046, covering new crystalline forms and multiple indications.
- Annovis Bio's buntanetap now includes a new crystalline form with proven bioequivalence and improved stability, as detailed in recent studies and presentations.
- Annovis Bio's advancements in neurodegenerative disease treatments promise to enhance patient outcomes and quality of life, marking a step forward in medical science.
- Discover how Annovis Bio's innovative buntanetap formulation could revolutionize neurodegenerative disease treatment, with patents secured through 2046.
Impact - Why it Matters
This news is crucial for patients, caregivers, and investors in the biotech sector. Annovis Bio's advancement in neurodegenerative disease treatment represents a significant step forward in addressing conditions like Alzheimer’s and Parkinson’s, which affect millions worldwide. The extended patent protection ensures the company's ability to develop and potentially bring to market a treatment that could improve patient outcomes and quality of life. For investors, this underscores Annovis Bio's position as a key player in the biotech industry, with a robust pipeline and intellectual property portfolio.
Summary
Annovis Bio Inc. (NYSE: ANVS), a pioneering late-stage clinical company focused on neurodegenerative diseases, has successfully expanded its intellectual property to cover new and original crystalline forms of buntanetap, a promising treatment. This development, ensuring patent protection through 2046, encompasses composition of matter, mechanism of action, and application across multiple indications. The new crystalline form boasts enhanced stability, with bioequivalence confirmed in both animal and human studies, a breakthrough presented at the 2025 Alzheimer’s Association International Conference. Annovis Bio, headquartered in Malvern, Pennsylvania, is at the forefront of developing innovative therapies aimed at improving the lives of patients suffering from Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). For more details, visit the full press release.
BioMedWire (BMW), a leading communications platform specializing in Biotechnology and Life Sciences, highlights this significant advancement. As part of the Dynamic Brand Portfolio under IBN, BMW offers comprehensive solutions for companies seeking to amplify their reach in the market. Discover more about their services at BioMedWire.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio Secures Patent for Breakthrough Neurodegenerative Treatment
